Scripta Insights, the doctor-driven, AI-powered pharmacy navigation company that guides self-insured employers, health plans and their members to prescription savings, announces today its GLP-1 ...

An FDA deadline instructing compounding pharmacies and telehealth companies to stop selling compounded versions of Ozempic and Zepbound has not stopped the copycat market, The Wall Street Journal ...

Novo Nordisk A/S NVO shares lost 2.7% on Friday after a surprising announcement regarding changes to its executive leadership ...

CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed ...

Novo Nordisk NVO shares have gained 13.9% in the past month. Several factors related to the company’s pipeline, regulatory ...

Illinois officials indicated that the settlement is about a larger issue than just a contract dispute with one PBM.

Despite its expensive valuation and declining estimates, we suggest investors hold LLY stock as the company boasts solid ...